Jazz Pharmaceuticals vs United Therapeutics
JAZZ and UTHR side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How JAZZ and UTHR compare
United Therapeutics is the larger company, worth 1.6 times as much as Jazz Pharmaceuticals ($25.2B against $15.6B).
On earnings, United Therapeutics is cheaper: it trades at 21.0× trailing earnings, against 78.1× for Jazz Pharmaceuticals.
Jazz Pharmaceuticals grew revenue faster over the last twelve months (13.5% versus 2.5% for United Therapeutics).
United Therapeutics keeps more of each dollar of sales as profit, with a net margin of 41.6% compared with 4.4% at Jazz Pharmaceuticals.
United Therapeutics scores higher on the StockData Score (11 against 7 for Jazz Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | JAZZ | UTHR |
|---|---|---|
| Size and price | ||
| Market cap | $15.6B | $25.2B |
| Share price | $239.77 | $587.88 |
| Change, 1 year | 69.2% | 27.2% |
| Change, 5 years | 93.2% | 204% |
| Beta (5Y) | 0.20 | 0.44 |
| Employees | 2,890 | 1,400 |
| StockData Score | ||
| Total score | 7 | 11 (better) |
| Valuation score | 0 | 1 (better) |
| Growth score | 2 | 2 |
| Performance score | 3 | 5 (better) |
| Health score | 2 | 3 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 78.1× | 21.0× (better) |
| P/S | 3.3× (better) | 8.0× |
| P/B | 3.7× (better) | 3.9× |
| EV/EBITDA | 42.9× | 15.1× (better) |
| P/FCF | 9.6× (better) | 23.1× |
| PEG | – | 0.92 |
| FCF yield | 10.4% (better) | 4.3% |
| Fair value | $108.36 | $480.40 |
| Margin of safety | −121% | −22.4% (better) |
| Growth | ||
| Revenue growth (TTM) | 13.5% (better) | 2.5% |
| Revenue growth, 5Y average | 12.5% | 16.5% (better) |
| Net income growth (TTM) | – | 5.5% |
| EPS growth (TTM) | – | 9.0% |
| EPS growth, 5Y average | – | 19.3% |
| Profitability | ||
| Gross margin | – | 86.1% |
| Operating margin | 9.0% | 44.4% (better) |
| Net margin | 4.4% | 41.6% (better) |
| FCF margin | 34.4% | 34.6% (better) |
| Return on equity | 5.1% | 19.3% (better) |
| Return on invested capital | 4.5% | 29.7% (better) |
| Financial health | ||
| Debt / equity | 1.33 | – |
| Net debt / EBITDA | 6.37 | – |
| Interest coverage | – | 117× |
| Current ratio | 1.82 | 5.73 (better) |
| Altman Z-score | 1.96 | 21.79 (better) |
| Piotroski F-score | 4 | 8 (better) |
| Dividends and buybacks | ||
| Buyback yield | – | 9.9% |
| Shareholder yield | 0.00% | 9.9% (better) |
| Ownership | ||
| Held by institutions | 99.2% | 97.4% |
| Held by insiders | 3.4% | 9.1% |
| Insider net buying, 12 months | −$67.1M (better) | −$1.4B |
| Superinvestors holding | 1 | – |
| Short interest, % of float | 9.3% | 4.7% |
Go deeper
- JAZZ stock overview
- JAZZ income statement
- JAZZ valuation and score
- UTHR stock overview
- UTHR income statement
- UTHR valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.